The significance of this finding extends beyond mere expression levels and touches upon HA metabolic patterns: the concurrent decrease in HYAL1 and total HA levels in tumor tissues suggests that alterations in HYAL1 expression may not directly determine the overall HA accumulation burden in breast cancer, but rather modulate the functional state and biological activity of HA molecules. The gene discussed is HYAL1; the disease is breast carcinoma.